WO2007017065A3 - Angiogenesis inhibition based upon icam 1 or junb expression levels - Google Patents

Angiogenesis inhibition based upon icam 1 or junb expression levels Download PDF

Info

Publication number
WO2007017065A3
WO2007017065A3 PCT/EP2006/007092 EP2006007092W WO2007017065A3 WO 2007017065 A3 WO2007017065 A3 WO 2007017065A3 EP 2006007092 W EP2006007092 W EP 2006007092W WO 2007017065 A3 WO2007017065 A3 WO 2007017065A3
Authority
WO
WIPO (PCT)
Prior art keywords
determining
subject
methods
disease
test sample
Prior art date
Application number
PCT/EP2006/007092
Other languages
French (fr)
Other versions
WO2007017065A2 (en
Inventor
Engeland Manon Van
Arjan W Griffioen
Original Assignee
Oncomethylome Sciences Sa
Engeland Manon Van
Arjan W Griffioen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0515471A external-priority patent/GB0515471D0/en
Application filed by Oncomethylome Sciences Sa, Engeland Manon Van, Arjan W Griffioen filed Critical Oncomethylome Sciences Sa
Priority to EP06762692A priority Critical patent/EP1907856A2/en
Publication of WO2007017065A2 publication Critical patent/WO2007017065A2/en
Publication of WO2007017065A3 publication Critical patent/WO2007017065A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Abstract

Methods for determining angiogenesis associated with a disease in a subject include the steps of, in a suitable test sample, determining expression levels of at least one gene selected from junB and ICAM 1. A statistically significant decrease in, or low level of, expression of one or both of the genes indicates the presence of angiogenesis associated with the disease in the subject. Preferably, the test sample includes endothelial cells. The method may further include determining the expression of THBSl and/or IGFBP3. Methods of determining angiogenesis in a subject may also include determining the level of acetylated histone H3 in the promote region of the IGFBP3 gene in a test sample. Pharmaceutical compositions for use in inhibiting angiogenesis include a DNA methyltransf erase inhibitor together with a pharmaceutically acceptable carrier and are in a form suitable for metronomic dosing. They may alternatively or additionally include a component allowing targeting to endothelial cells. Methods of preventing or inhibiting angiogenesis associated with a disease in a subject involve administering a therapeutically effective amount of a DNA methyltransf erase inhibitor. Treatment regimes, microarrays and screening methods are also described.
PCT/EP2006/007092 2005-07-27 2006-07-19 Angiogenesis inhibition based upon icam 1 or junb expression levels WO2007017065A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06762692A EP1907856A2 (en) 2005-07-27 2006-07-19 Angiogenesis inhibition based upon icam 1 or junb expression levels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70258205P 2005-07-27 2005-07-27
GB0515471A GB0515471D0 (en) 2005-07-27 2005-07-27 Angiogenesis inhibition
US60/702,582 2005-07-27
GB0515471.1 2005-07-27

Publications (2)

Publication Number Publication Date
WO2007017065A2 WO2007017065A2 (en) 2007-02-15
WO2007017065A3 true WO2007017065A3 (en) 2007-05-24

Family

ID=37546761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007092 WO2007017065A2 (en) 2005-07-27 2006-07-19 Angiogenesis inhibition based upon icam 1 or junb expression levels

Country Status (2)

Country Link
EP (1) EP1907856A2 (en)
WO (1) WO2007017065A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109810A2 (en) 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
EP3238726A3 (en) 2010-12-22 2018-01-10 Idogen AB Composition comprising interferon gamma and an hdac inhibitor or gonadotropin receptor signalling hormone
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
US11229662B2 (en) 2016-11-15 2022-01-25 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN109771647A (en) * 2019-01-28 2019-05-21 首都儿科研究所 Application of the dnmt rna inhibitor in building neural tube malformation mouse model

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400806A1 (en) * 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
WO2005007193A2 (en) * 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400806A1 (en) * 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
WO2005007193A2 (en) * 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHANG Y, S. ET AL: "mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cnacer", ONCOGENE, vol. 23, 12 July 2004 (2004-07-12), pages 6569 - 6580, XP002425230 *
HELLEBREKERS DEBBY M E I ET AL: "Angiostatic activity of DNA methyltransferase inhibitors.", MOLECULAR CANCER THERAPEUTICS. FEB 2006, vol. 5, no. 2, February 2006 (2006-02-01), pages 467 - 475, XP002413140, ISSN: 1535-7163 *
HELLEBREKERS DEBBY M E I ET AL: "Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications.", CANCER RESEARCH 15 NOV 2006, vol. 66, no. 22, 15 November 2006 (2006-11-15), pages 10770 - 10777, XP002413139, ISSN: 0008-5472 *
KIM M S ET AL: "Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 7, no. 4, April 2001 (2001-04-01), pages 437 - 443, XP002278083, ISSN: 1078-8956 *
SHEIBANI NADER ET AL: "Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells", CANCER LETTERS, vol. 107, no. 1, 1996, pages 45 - 52, XP002413137, ISSN: 0304-3835 *
ST CROIX B ET AL: "Genes expressed in human tumor endothelium", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 289, no. 5482, 18 August 2000 (2000-08-18), pages 1197 - 1292, XP002201336, ISSN: 0036-8075 *
TSUBAKI JUNKO ET AL: "Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells", ENDOCRINOLOGY, vol. 143, no. 5, May 2002 (2002-05-01), pages 1778 - 1788, XP002425229, ISSN: 0013-7227 *
VAN DER VELDEN P A ET AL: "Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 106, no. 4, 10 September 2003 (2003-09-10), pages 472 - 479, XP002389348, ISSN: 0020-7136 *
VILLAR-GAREA ANA ET AL: "Histone deacetylase inhibitors: Understanding a new wave of anticancer agents", INTERNATIONAL JOURNAL OF CANCER, vol. 112, no. 2, 1 November 2004 (2004-11-01), pages 171 - 178, XP002413155, ISSN: 0020-7136 *
YANG QI-WEI ET AL: "Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.", CANCER RESEARCH, vol. 63, no. 19, 1 October 2003 (2003-10-01), pages 6299 - 6310, XP002413138, ISSN: 0008-5472 *
YOHRLING J W ET AL: "EXPRESSION OF NORMAL AND TUMOR ENDOTHELIAL CELL MARKERS IN MOUSE ENDOTHELIAL CELLS IN VITRO AND IN VIVO", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 44, July 2003 (2003-07-01), pages 407 - 408, XP008034731, ISSN: 0197-016X *

Also Published As

Publication number Publication date
EP1907856A2 (en) 2008-04-09
WO2007017065A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
Senft et al. Ubiquitin ligases in oncogenic transformation and cancer therapy
Herrington et al. Modulation of NF-κB signaling as a therapeutic target in autoimmunity
Yang et al. KIF14 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in human gastric cancer
Van der Velden et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development
WO2007017065A3 (en) Angiogenesis inhibition based upon icam 1 or junb expression levels
Shah et al. Targeting ribonucleotide reductase M2 and NF-κB activation with didox to circumvent tamoxifen resistance in breast cancer
WO2007112330A3 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
EP3552607A3 (en) Imidazopyrazine syk inhibitors
WO2005067391A3 (en) Diagnostic test for parkinson's disease
Kazmers et al. Hedgehog signaling mediates woven bone formation and vascularization during stress fracture healing
WO2007085497A3 (en) Markers for the prediction of outcome of anthracycline treatment
US11946053B2 (en) Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer
US20180051344A1 (en) Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis
Tsolou et al. ‘Stemness’ and ‘senescence’related escape pathways are dose dependent in lung cancer cells surviving post irradiation
Ouyang et al. STIL is upregulated in nasopharyngeal carcinoma tissues and promotes nasopharyngeal carcinoma proliferation, migration and invasion.
Ambriovic-Ristov et al. Integrin-mediated drug resistance
WO2006027463A3 (en) Biochip for determining sensitivity to an anticancer drug
Shibata et al. ATM: Its Recruitment, Activation, Signalling and Contribution to Tumour Suppression
Zhang et al. Negative growth regulators of the cell cycle machinery and cancer
Lokugamage et al. Breast cancer in relation to childhood parental divorce and early adult psychiatric disorder in a British birth cohort
Helfricht Chromatin modifiers in DNA repair and human disease
Burmi et al. Microarray studies reveal novel genes associated with endocrine resistance in breast cancer
Ottewell et al. Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo
Marfe et al. Emerging Roles of the Sirtuin Family in Cancer
CN101979657A (en) Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006762692

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006762692

Country of ref document: EP